ZA9806729B - Irreversible inhibitors of tyrosine kinases - Google Patents

Irreversible inhibitors of tyrosine kinases

Info

Publication number
ZA9806729B
ZA9806729B ZA9806729A ZA9806729A ZA9806729B ZA 9806729 B ZA9806729 B ZA 9806729B ZA 9806729 A ZA9806729 A ZA 9806729A ZA 9806729 A ZA9806729 A ZA 9806729A ZA 9806729 B ZA9806729 B ZA 9806729B
Authority
ZA
South Africa
Prior art keywords
tyrosine kinases
irreversible inhibitors
irreversible
inhibitors
kinases
Prior art date
Application number
ZA9806729A
Inventor
Alexander James Bridges
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US5406197P priority Critical
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA9806729B publication Critical patent/ZA9806729B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
ZA9806729A 1997-07-29 1998-07-28 Irreversible inhibitors of tyrosine kinases ZA9806729B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US5406197P true 1997-07-29 1997-07-29

Publications (1)

Publication Number Publication Date
ZA9806729B true ZA9806729B (en) 1999-02-02

Family

ID=21988531

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9806729A ZA9806729B (en) 1997-07-29 1998-07-28 Irreversible inhibitors of tyrosine kinases

Country Status (4)

Country Link
US (2) US6153617A (en)
AU (1) AU8665998A (en)
WO (1) WO1999006396A1 (en)
ZA (1) ZA9806729B (en)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2289791T3 (en) 1997-08-22 2008-02-01 Astrazeneca Ab Oxindolilquinazolina derivatives as angiogenesis inhibitors.
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
SK287805B6 (en) 1998-08-18 2011-10-04 The Regents Of The University Of California Use of epidermal growth factor receptor (EGF-R) antagonist for the manufacture of a medicament for the treatment of hypersecretion of mucus in airways
AU763618B2 (en) 1999-02-10 2003-07-31 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
DK1731511T3 (en) 1999-06-21 2015-10-26 Boehringer Ingelheim Pharma Bicyclic heterocyclic structures, pharmaceutical compositions containing these compounds, their use and process for their preparation
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
JP2003504363A (en) * 1999-07-09 2003-02-04 グラクソ グループ リミテッド Anilinoquinazoline such as protein tyrosine kinase inhibitors
PT1244647E (en) 1999-11-05 2006-10-31 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
MXPA02009855A (en) * 2000-04-08 2003-03-27 Boehringer Ingelheim Pharma Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them.
PT1287001E (en) * 2000-06-06 2004-12-31 Pfizer Prod Inc Utious thyrofen derivatives as anticancerigene agents
EP1318984A1 (en) * 2000-09-20 2003-06-18 MERCK PATENT GmbH 4-amino-quinazolines
US7829566B2 (en) * 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
HU0302429A3 (en) * 2000-09-20 2004-01-28 Merck Patent Gmbh 4-amino-quinazolines, process for producing them, pharmaceutical compositions containing them and their use
AU9213701A (en) * 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10063435A1 (en) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate medicaments containing these compounds, their use and processes for their preparation
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
UY27224A1 (en) * 2001-03-23 2002-10-31 Bayer Corp Inhibitors rho kinase
PE09582002A1 (en) * 2001-03-23 2002-11-14 Bayer Corp Inhibitors rho kinase
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc Novel quinazolines and uses thereof
EP1465632A1 (en) * 2001-12-12 2004-10-13 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
DE60320933D1 (en) * 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitors
WO2003062227A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
JP4469179B2 (en) * 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Pyrimidine derivatives as Rho-kinase inhibitors
US7268230B2 (en) * 2002-02-01 2007-09-11 Astrazeneca Ab Quinazoline compounds
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
DE10221018A1 (en) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Use of inhibitors of EGFR-mediated signal transduction in the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
AU2003273218C1 (en) 2002-07-15 2019-01-17 F. Hoffmann - La Roche Ag Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
WO2004011456A1 (en) * 2002-07-31 2004-02-05 Danter Wayne R Protein tyrosine kinase inhibitors
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc Fc varieties with optimized fc receptor binding properties
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ES2562177T3 (en) 2002-09-27 2016-03-02 Xencor Inc. Optimized Fc variants and methods for their generation
WO2004033446A1 (en) * 2002-10-09 2004-04-22 Danter Wayne R Protein tyrosine kinase inhibitors
AU2003299943A1 (en) * 2002-12-23 2004-07-22 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
WO2005000197A2 (en) 2003-04-11 2005-01-06 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (en) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma A process for preparing Aminocrotonylverbindungen
JP5020636B2 (en) 2003-11-06 2012-09-05 シアトル ジェネティックス, インコーポレイテッド Monomethylvaline compounds that can be conjugated to a ligand
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
EP1740184A1 (en) * 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinations of signal transduction inhibitors
KR101368446B1 (en) 2004-03-31 2014-02-28 다나-파버 캔서 인스티튜트 인크. Method for determining the likelihood of effectiveness of an epidermal growth factor receptor targeting treatment in a human patient affected with cancer, kit, nucleic acid probe, primer pair, and isolated protein
AP2204A (en) * 2004-05-06 2011-02-07 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides.
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
EP3342782A1 (en) 2004-07-15 2018-07-04 Xencor, Inc. Optimized fc variants
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
AR050948A1 (en) 2004-09-24 2006-12-06 Hoffmann La Roche Phthalazinone derivatives; their preparation and their use in the manufacture of drugs for the treatment of cancer.
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006053301A2 (en) 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
SI1850874T1 (en) 2005-02-23 2014-01-31 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
AU2006233537A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
AU2006288716A1 (en) * 2005-09-06 2007-03-15 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal growth factor receptor tyrosine kinase
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
AU2007221049A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
ME01786B (en) 2006-08-14 2014-09-20 Xencor Inc Optimized antibodies that target cd19
ES2372217T3 (en) 2006-09-12 2012-01-17 Genentech, Inc. Procedures and compositions for the diagnosis and treatment of lung cancer using the gene of pdgfra, kit or kdr as a genetic marker.
US8877764B2 (en) * 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
EP2121681B1 (en) 2007-01-11 2015-04-15 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
JP2010520225A (en) 2007-03-02 2010-06-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Method of predicting the response to her dimerization inhibitor based on low her3 expression
LT2176298T (en) 2007-05-30 2018-04-10 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
ES2417148T3 (en) 2007-06-08 2013-08-06 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2009081222A1 (en) * 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
MX2010008621A (en) 2008-02-07 2010-09-24 Boehringer Ingelheim Int Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production.
WO2009140409A1 (en) 2008-05-14 2009-11-19 Genomic Health Inc. Predictors of patient response to treatment with egf receptor inhibitors
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010006438A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2313397B1 (en) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy substituted heterocycles, medicine containing these connections, their application and production method
JP5963672B2 (en) 2009-07-06 2016-08-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング BIBW2992, a salt thereof and a method for drying a solid pharmaceutical preparation comprising this active ingredient
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP2523957A1 (en) 2010-01-12 2012-11-21 F.Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
JP2013521487A (en) 2010-03-04 2013-06-10 カルペン,オッリ Method for selecting a patient for treatment with an EGFR inhibitor
RU2012141536A (en) 2010-03-17 2014-04-27 Ф. Хоффманн-Ля Рош Аг Imidazopyridines, compositions and methods of application
CA2794745A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
KR20130058672A (en) 2010-04-16 2013-06-04 제넨테크, 인크. Foxo3a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
BR112012031340A2 (en) 2010-06-09 2016-11-01 Tianjin Hemay Bio Tech Co Ltd cyanoquinoline derivatives
JP5822934B2 (en) 2010-09-15 2015-11-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Azabenzothiazole compounds, compositions and methods of use
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
CN103313987A (en) 2010-11-19 2013-09-18 弗·哈夫曼-拉罗切有限公司 Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
WO2012122513A2 (en) 2011-03-10 2012-09-13 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
CN102898386B (en) 2011-07-27 2015-07-29 上海医药集团股份有限公司 Quinazoline derivatives, their preparation, intermediates, compositions and uses thereof
CA2844289A1 (en) 2011-08-12 2013-02-21 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
KR20140047160A (en) 2011-08-12 2014-04-21 에프. 호프만-라 로슈 아게 Indazole compounds, compositions and methods of use
KR20140082710A (en) 2011-09-20 2014-07-02 에프. 호프만-라 로슈 아게 Imidazopyridine compounds, compositions and methods of use
BR112014022228A2 (en) 2012-03-08 2017-07-11 Halozyme Inc conditionally active growth factor receptor anti-epidermal antibodies and methods of using them
AU2013240261A1 (en) 2012-03-27 2014-09-18 Genentech, Inc. Diagnosis and treatments relating to HER3 inhibitors
CN102786512A (en) 2012-05-31 2012-11-21 中国人民解放军军事医学科学院毒物药物研究所 N-aryl unsaturated fused ring tertiary amine compound, preparation method thereof and application thereof to tumor resistance
AU2014216178B2 (en) 2013-02-15 2018-06-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CN107915751A (en) 2013-02-20 2018-04-17 卡拉制药公司 Therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CA2903657A1 (en) 2013-02-27 2014-09-04 Shionogi & Co., Ltd. Indole and azaindole derivatives each having ampk-activating activity
US10035801B2 (en) 2013-03-13 2018-07-31 Genentech, Inc. Pyrazolo compounds and uses thereof
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
PL2970101T3 (en) 2013-03-14 2018-11-30 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various deseases
CN104163815B (en) * 2013-05-17 2017-11-28 温州医学院 Indole-containing quinazoline compounds and in the treatment of diseases dependent tumor egfr
KR20160049003A (en) 2013-09-05 2016-05-04 제넨테크, 인크. Antiproliferative compounds
BR112016005526A2 (en) 2013-09-12 2017-09-12 Halozyme Inc modified anti-epidermal growth factor receptor antibodies and methods of use
WO2015049325A1 (en) 2013-10-03 2015-04-09 F. Hoffmann-La Roche Ag Therapeutic inhibitors of cdk8 and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
SG11201604956SA (en) 2013-12-17 2016-07-28 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CA2940845A1 (en) 2014-02-24 2015-08-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
EP3126386A1 (en) 2014-03-31 2017-02-08 F.Hoffmann-La Roche Ag Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
KR20160145624A (en) 2014-03-31 2016-12-20 제넨테크, 인크. Anti-ox40 antibodies and methods of use
CN106414397B (en) * 2014-04-16 2019-02-12 南洋理工大学 The allene amide as orthogonal handle for the selective modification of cysteine in peptide and protein
WO2016036873A1 (en) 2014-09-05 2016-03-10 Genentech, Inc. Therapeutic compounds and uses thereof
JP2017529358A (en) 2014-09-19 2017-10-05 ジェネンテック, インコーポレイテッド Use of CBP / EP300 inhibitors and BET inhibitors for the treatment of cancer
EP3204379B1 (en) 2014-10-10 2019-03-06 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
US20160161485A1 (en) 2014-11-03 2016-06-09 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
MX2017005929A (en) 2014-11-06 2017-11-20 Genentech Inc Combination therapy comprising ox40 binding agonists and tigit inhibitors.
JP2017533249A (en) 2014-11-10 2017-11-09 ジェネンテック, インコーポレイテッド Substituted pyrrolopyridines as inhibitors of bromodomains
WO2016077378A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Substituted pyrrolopyrdines as inhibitors of bromodomain
EP3218376A1 (en) 2014-11-10 2017-09-20 Genentech, Inc. Bromodomain inhibitors and uses thereof
WO2016081384A1 (en) 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3224258B1 (en) 2014-11-27 2019-08-14 Genentech, Inc. 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
CA2968359A1 (en) 2014-12-23 2016-06-30 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
CN107208138A (en) 2014-12-30 2017-09-26 豪夫迈·罗氏有限公司 Methods and compositions for prognosis and treatment of cancers
CN107406429A (en) 2015-01-09 2017-11-28 基因泰克公司 Pyridazinone derivatives and their use in the treatment of cancer
EP3242872B1 (en) 2015-01-09 2019-07-03 Genentech, Inc. (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
EP3242875A1 (en) 2015-01-09 2017-11-15 Genentech, Inc. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
EP3250571A1 (en) 2015-01-29 2017-12-06 Genentech, Inc. Therapeutic compounds and uses thereof
CN107438593A (en) 2015-01-30 2017-12-05 基因泰克公司 Therapeutic compounds and uses thereof
CN107531668A (en) 2015-02-25 2018-01-02 基因泰克公司 Therapeutic pyridazine compounds and uses thereof
JP2018516537A (en) 2015-04-07 2018-06-28 ジェネンテック, インコーポレイテッド Antigen binding complex having agonistic activity and method of use thereof
CA2984003A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP3303397A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
WO2016200836A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
JP2018528201A (en) 2015-08-26 2018-09-27 ファンダシオン デル セクトル プーブリコ エスタタル セントロ ナショナル デ インベスティゲーショネス オンコロジカス カルロス 3(エフ エス ピー クニオ) Condensed tricyclic compounds as protein kinase inhibitors
EP3423596A1 (en) 2016-02-29 2019-01-09 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP3443350A2 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Methods for monitoring and treating cancer
CA3020718A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
MX2018012471A (en) 2016-04-15 2019-02-21 Genentech Inc Diagnostic and therapeutic methods for cancer.
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
WO2017205538A1 (en) 2016-05-24 2017-11-30 Genentech, Inc. Pyrazolopyridine derivatives for the treatment of cancer
WO2017205536A2 (en) 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
EP3469099A1 (en) 2016-06-08 2019-04-17 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
WO2017214452A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
EP3494139A1 (en) 2016-08-05 2019-06-12 H. Hoffnabb-La Roche Ag Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
EP3497129A1 (en) 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Therapeutic and diagnostic methods for cancer
CN106831725B (en) * 2016-08-09 2019-08-20 江西科技师范大学 The quinazoline compounds and its application of quinoline containing indoline and similar structures
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN109688818A (en) 2016-09-08 2019-04-26 卡拉制药公司 Crystal form of therapeutic compounds and application thereof
AU2017339517A1 (en) 2016-10-06 2019-04-18 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
AU2018228873A1 (en) 2017-03-01 2019-08-29 Genentech, Inc. Diagnostic and therapeutic methods for cancer
AU2018250875A1 (en) 2017-04-13 2019-10-03 F. Hoffmann-La Roche Ag An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
WO2019018757A1 (en) 2017-07-21 2019-01-24 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2019033043A2 (en) 2017-08-11 2019-02-14 Genentech, Inc. Anti-cd8 antibodies and uses thereof
TW201919707A (en) 2017-09-08 2019-06-01 美商建南德克公司 Diagnostic and therapeutic methods for cancer
TW201923089A (en) 2017-11-06 2019-06-16 美商建南德克公司 Diagnostic and therapeutic methods for cancer
WO2019148036A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019148044A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019148043A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019165434A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
PT100905A (en) * 1991-09-30 1994-02-28 Eisai Co Ltd Bicycle hygieneous heterocyclic compounds containing benzene, cyclohexan or pyridine and pyrimidine, pyridine or imidazole substitutes and pharmaceutical compositions containing them
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
RU2137762C1 (en) * 1994-02-23 1999-09-20 Пфайзер Инк. 4-heterocyclyl-substituted derivative of quinazoline, pharmaceutical composition
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
AT213730T (en) * 1996-04-12 2002-03-15 Warner Lambert Co kinases reversible inhibitors of tyrosine
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CN1237177A (en) * 1996-11-27 1999-12-01 辉瑞大药厂 Fused bicyclic pyrimidine derivatives

Also Published As

Publication number Publication date
AU8665998A (en) 1999-02-22
US6153617A (en) 2000-11-28
US20030087881A1 (en) 2003-05-08
WO1999006396A1 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
GB2346877B (en) 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
PL186843B1 (en) Derivatives of quinazoline
PL189182B1 (en) Derivatives of quinazoline
AU3766897A (en) Fused heterocyclic compounds as protein tyrosine kinase inhibitors
EP1259235A4 (en) Tyrosine kinase inhibitors
HU0103633A3 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhib
PT1117659E (en) Substituted cyanochinolines as protein tyrosine kinase inhibitors
PL343611A1 (en) Inhibitors of caspases
ZA9703146B (en) Prodrugs of COX-2 inhibitors.
HUT76622A (en) Inhibitors of interlaukin-1beta converting enzyme
PL331338A1 (en) Thiosulphonamidic metaloprotease inhibitors
ZA9805778B (en) Inhibitors of farnesyl protein transferase.
AU3443997A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU3693697A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
PL323710A1 (en) Reversible inhibitors of cysteinic protease
AU5783300A (en) Anilinoquinazolines as protein tyrosine kinase inhibitors
PL322549A1 (en) Inhibitors of proteinous farnesiltransferase
SI1070056T1 (en) Phthalazinone pde iii/iv inhibitors
HU0000053A3 (en) Hppd gene and inhibitors
AU5610598A (en) Substituted nitrogen containing heterocycles as inhibitors of p38 protein kinase
PL202845B1 (en) Sulphonamidic derivatives useful as precursors of aspartil protease inhibitors
AU7167298A (en) Inhibitors of the jnk signal transduction pathway and methods of use
MX202707B (en) Scale inhibitors
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
RU2000115305A (en) AMINOTRIASOL INHIBITORS OF CYCLIN-dependent KINAZ